Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?

The ketogenic diet’s (KD) anticonvulsant effects have been well-documented for nearly a century, including in randomized controlled trials. Some patients become seizure-free and some remain so after diet cessation. Many recent studies have explored its expanded therapeutic potential in diverse neuro...

Full description

Bibliographic Details
Main Authors: Marwa Elamin, David N. Ruskin, Susan A. Masino, Paola Sacchetti
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-11-01
Series:Frontiers in Molecular Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fnmol.2017.00377/full
id doaj-e1ac25be1e924c038202d773751a4bb7
record_format Article
spelling doaj-e1ac25be1e924c038202d773751a4bb72020-11-24T22:25:30ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992017-11-011010.3389/fnmol.2017.00377297591Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?Marwa Elamin0David N. Ruskin1Susan A. Masino2Paola Sacchetti3Neuroscience Program, Department of Biology, University of Hartford, West Hartford, CT, United StatesNeuroscience Program and Psychology Department, Trinity College, Hartford, CT, United StatesNeuroscience Program and Psychology Department, Trinity College, Hartford, CT, United StatesNeuroscience Program, Department of Biology, University of Hartford, West Hartford, CT, United StatesThe ketogenic diet’s (KD) anticonvulsant effects have been well-documented for nearly a century, including in randomized controlled trials. Some patients become seizure-free and some remain so after diet cessation. Many recent studies have explored its expanded therapeutic potential in diverse neurological disorders, yet no mechanism(s) of action have been established. The diet’s high fat, low carbohydrate composition reduces glucose utilization and promotes the production of ketone bodies. Ketone bodies are a more efficient energy source than glucose and improve mitochondrial function and biogenesis. Cellular energy production depends on the metabolic coenzyme nicotinamide adenine dinucleotide (NAD), a marker for mitochondrial and cellular health. Furthermore, NAD activates downstream signaling pathways (such as the sirtuin enzymes) associated with major benefits such as longevity and reduced inflammation; thus, increasing NAD is a coveted therapeutic endpoint. Based on differential NAD+ utilization during glucose- vs. ketone body-based acetyl-CoA generation for entry into the tricarboxylic cycle, we propose that a KD will increase the NAD+/NADH ratio. When rats were fed ad libitum KD, significant increases in hippocampal NAD+/NADH ratio and blood ketone bodies were detected already at 2 days and remained elevated at 3 weeks, indicating an early and persistent metabolic shift. Based on diverse published literature and these initial data we suggest that increased NAD during ketolytic metabolism may be a primary mechanism behind the beneficial effects of this metabolic therapy in a variety of brain disorders and in promoting health and longevity.http://journal.frontiersin.org/article/10.3389/fnmol.2017.00377/fullketone bodiesmetabolismhippocampusepilepsyneurodegenerationAlzheimer’s disease
collection DOAJ
language English
format Article
sources DOAJ
author Marwa Elamin
David N. Ruskin
Susan A. Masino
Paola Sacchetti
spellingShingle Marwa Elamin
David N. Ruskin
Susan A. Masino
Paola Sacchetti
Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?
Frontiers in Molecular Neuroscience
ketone bodies
metabolism
hippocampus
epilepsy
neurodegeneration
Alzheimer’s disease
author_facet Marwa Elamin
David N. Ruskin
Susan A. Masino
Paola Sacchetti
author_sort Marwa Elamin
title Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?
title_short Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?
title_full Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?
title_fullStr Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?
title_full_unstemmed Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?
title_sort ketone-based metabolic therapy: is increased nad+ a primary mechanism?
publisher Frontiers Media S.A.
series Frontiers in Molecular Neuroscience
issn 1662-5099
publishDate 2017-11-01
description The ketogenic diet’s (KD) anticonvulsant effects have been well-documented for nearly a century, including in randomized controlled trials. Some patients become seizure-free and some remain so after diet cessation. Many recent studies have explored its expanded therapeutic potential in diverse neurological disorders, yet no mechanism(s) of action have been established. The diet’s high fat, low carbohydrate composition reduces glucose utilization and promotes the production of ketone bodies. Ketone bodies are a more efficient energy source than glucose and improve mitochondrial function and biogenesis. Cellular energy production depends on the metabolic coenzyme nicotinamide adenine dinucleotide (NAD), a marker for mitochondrial and cellular health. Furthermore, NAD activates downstream signaling pathways (such as the sirtuin enzymes) associated with major benefits such as longevity and reduced inflammation; thus, increasing NAD is a coveted therapeutic endpoint. Based on differential NAD+ utilization during glucose- vs. ketone body-based acetyl-CoA generation for entry into the tricarboxylic cycle, we propose that a KD will increase the NAD+/NADH ratio. When rats were fed ad libitum KD, significant increases in hippocampal NAD+/NADH ratio and blood ketone bodies were detected already at 2 days and remained elevated at 3 weeks, indicating an early and persistent metabolic shift. Based on diverse published literature and these initial data we suggest that increased NAD during ketolytic metabolism may be a primary mechanism behind the beneficial effects of this metabolic therapy in a variety of brain disorders and in promoting health and longevity.
topic ketone bodies
metabolism
hippocampus
epilepsy
neurodegeneration
Alzheimer’s disease
url http://journal.frontiersin.org/article/10.3389/fnmol.2017.00377/full
work_keys_str_mv AT marwaelamin ketonebasedmetabolictherapyisincreasednadaprimarymechanism
AT davidnruskin ketonebasedmetabolictherapyisincreasednadaprimarymechanism
AT susanamasino ketonebasedmetabolictherapyisincreasednadaprimarymechanism
AT paolasacchetti ketonebasedmetabolictherapyisincreasednadaprimarymechanism
_version_ 1725757228710887424